ANK-302

N/A

Report date: 2026/03/11 20:02:12
NME

Base Information

Drug NameANK-302
Drug Alias NameANK-302ANK302
ClassificationOther
Mechanisms of ActionT-cell-specific surface glycoprotein CD28 agonistsInterleukin-2 agonists
TargetsT-cell-specific surface glycoprotein CD28Interleukin-2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAnkyra Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAnkyra Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A